Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2+ mCRC

September 14th 2024

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

Dr Kim on the Safety of NT-17 Plus Pembrolizumab in Pretreated CRC and PDAC

September 11th 2024

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment

September 1st 2024

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued

August 30th 2024

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Dr Dasari on Salvage Treatment Considerations for Unresectable Metastatic CRC

August 30th 2024

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Fruquintinib Represents a Novel Therapeutic Approach in Advanced mCRC

August 30th 2024

Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for patients with advanced metastatic colorectal cancer.

Oxaliplatin Plus Fluoropyrimidine/Bevacizumab Does Not Improve Survival in Older Patients With mCRC

August 29th 2024

Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.

Dr Strickler on the Significance of Fruquintinib for Patients With Refractory mCRC

August 28th 2024

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

August 21st 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Dr Parikh on the Rationale for Adding ERAS-007 to the BEACON Regimen in BRAF V600E–Mutant mCRC

August 21st 2024

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

Dr Kim on Current Unmet Needs in the Management of Resectable CRC

August 16th 2024

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRC

August 15th 2024

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Dr Adam on Efforts to Reduce Recurrence Risk in CRC Liver Metastases

August 15th 2024

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

August 15th 2024

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Dr Bekaii-Saab on the Final Analysis of MOUNTAINEER in HER2+ CRC

August 8th 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Guardant Reveal Test Is Effective in Predicting Recurrence in Stage II and Higher CRC

August 7th 2024

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

ABBV-400 Demonstrates Preliminary Efficacy, Safety in MSS/pMMR Advanced CRC

August 1st 2024

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.